JP2010504336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504336A5 JP2010504336A5 JP2009529248A JP2009529248A JP2010504336A5 JP 2010504336 A5 JP2010504336 A5 JP 2010504336A5 JP 2009529248 A JP2009529248 A JP 2009529248A JP 2009529248 A JP2009529248 A JP 2009529248A JP 2010504336 A5 JP2010504336 A5 JP 2010504336A5
- Authority
- JP
- Japan
- Prior art keywords
- gly
- asp
- item
- pro
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 150000001413 amino acids Chemical group 0.000 claims description 78
- 108090000190 Thrombin Proteins 0.000 claims description 70
- 229960004072 thrombin Drugs 0.000 claims description 70
- 235000001014 amino acid Nutrition 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 40
- 210000004899 c-terminal region Anatomy 0.000 claims description 28
- 239000000556 agonist Substances 0.000 claims description 14
- 150000001408 amides Chemical group 0.000 claims description 13
- 239000000539 dimer Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 108020002447 serine esterase Proteins 0.000 claims description 6
- 102000005428 serine esterase Human genes 0.000 claims description 6
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 230000002491 angiogenic effect Effects 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 239000003869 thrombin derivative Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 108091036078 conserved sequence Proteins 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 102000058223 human VEGFA Human genes 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- -1 SEQ ID NO: 2 amino acids Chemical class 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000003225 hyperhomocysteinemia Effects 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 230000008816 organ damage Effects 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000004819 osteoinduction Effects 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 93
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 9
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 7
- 102000003790 Thrombin receptors Human genes 0.000 description 6
- 108090000166 Thrombin receptors Proteins 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- HZKLCOYAVAAQRD-VGMNWLOBSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxyethyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N HZKLCOYAVAAQRD-VGMNWLOBSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- OAPNERBWQWUPTI-YUMQZZPRSA-N Lys-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O OAPNERBWQWUPTI-YUMQZZPRSA-N 0.000 description 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010086780 arginyl-glycyl-aspartyl-alanine Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84641806P | 2006-09-22 | 2006-09-22 | |
| US84800406P | 2006-09-28 | 2006-09-28 | |
| US92264607P | 2007-04-10 | 2007-04-10 | |
| PCT/US2007/020445 WO2008036387A2 (en) | 2006-09-22 | 2007-09-21 | Method of treating endothelial dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013089123A Division JP2013166774A (ja) | 2006-09-22 | 2013-04-22 | 血管内皮機能不全を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504336A JP2010504336A (ja) | 2010-02-12 |
| JP2010504336A5 true JP2010504336A5 (enExample) | 2010-11-11 |
Family
ID=39201107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529248A Pending JP2010504336A (ja) | 2006-09-22 | 2007-09-21 | 血管内皮機能不全を治療する方法 |
| JP2013089123A Pending JP2013166774A (ja) | 2006-09-22 | 2013-04-22 | 血管内皮機能不全を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013089123A Pending JP2013166774A (ja) | 2006-09-22 | 2013-04-22 | 血管内皮機能不全を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8334259B2 (enExample) |
| EP (1) | EP2063910A2 (enExample) |
| JP (2) | JP2010504336A (enExample) |
| CN (1) | CN101563102B (enExample) |
| CA (1) | CA2663547C (enExample) |
| TW (1) | TWI486168B (enExample) |
| WO (1) | WO2008036387A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2155236A1 (en) * | 2007-04-10 | 2010-02-24 | The Board of Regents,The University of Texas System | Combination therapy for cardiac revascularization and cardiac repair |
| WO2009142679A2 (en) * | 2008-03-26 | 2009-11-26 | Orthologic Corp. | Methods for treating acute myocardial infarction |
| AU2009229402A1 (en) * | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Method of treating peripheral arterial disease |
| AU2009229395A1 (en) * | 2008-03-26 | 2009-10-01 | The Board Of Regents, The University Of Texas System | Method of treating degenerative diseases |
| EP2282765A1 (en) * | 2008-03-26 | 2011-02-16 | Orthologic Corp. | Thrombin derived peptides for smooth muscle relaxation |
| GB0916576D0 (en) | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| JP2013529600A (ja) * | 2010-06-11 | 2013-07-22 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法 |
| US10220078B2 (en) | 2014-06-11 | 2019-03-05 | The Board Of Regents Of The University Of Texas System | Methods of using thrombin derivatives to treat medulloblastoma |
| US10881686B2 (en) | 2017-10-27 | 2021-01-05 | Zeta Biolongevity, Inc | Compositions and methods for treating and preventing proteinuria and endothelial erosion |
| US10905738B2 (en) * | 2018-07-05 | 2021-02-02 | Biozeus Desenvolvimento De Produtos Biofarmacêuticos | Synthetic peptides, prodrugs, pharmaceutical compositions and uses |
| CN113092756A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液凝血酶原及其多肽片段在过敏性疾病中的应用 |
| EP4132948A4 (en) * | 2020-04-07 | 2024-01-03 | Chrysalis Biotherapeutics | TP5088 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352664A (en) | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| US5244460A (en) | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
| AU6778794A (en) | 1993-04-29 | 1994-11-21 | Washington University | Use of platelet-derived growth factor to improve collateral circulation |
| WO1997015598A1 (fr) | 1995-10-24 | 1997-05-01 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Nouveau peptide |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| US6197751B1 (en) | 1997-11-10 | 2001-03-06 | The United States Of America As Represented By The Department Of Health And Human Services | Thymosin α1 promotes tissue repair, angiogenesis and cell migration |
| US6033436A (en) | 1998-02-17 | 2000-03-07 | Md3, Inc. | Expandable stent |
| CA2329010A1 (en) | 1998-04-17 | 1999-10-28 | Angiogenix Incorporated | Therapeutic angiogenic factors and methods for their use |
| ATE275417T1 (de) | 1998-10-26 | 2004-09-15 | Ludwig Inst Cancer Res | Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose |
| US6363938B2 (en) | 1998-12-22 | 2002-04-02 | Angiotrax, Inc. | Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth |
| TWI257307B (en) | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
| ATE277174T1 (de) * | 2000-07-20 | 2004-10-15 | Univ Texas | Stimulation des knorpelwachstums mit agonisten des nicht-proteolytisch aktivierten thrombin rezeptors |
| CN100372567C (zh) * | 2002-01-16 | 2008-03-05 | 奥索洛吉艾斯有限公司 | 促进心脏组织修复的凝血酶衍生肽 |
| AU2003256343B2 (en) * | 2002-07-02 | 2006-12-21 | Orthologic Corp. | Thrombin peptide derivatives |
| CA2491135A1 (en) * | 2002-07-02 | 2004-01-15 | The Board Of Regents, The University Of Texas System | Thrombin peptide derivative dimers |
| JP5044829B2 (ja) * | 2003-12-31 | 2012-10-10 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | トロンビンペプチド誘導体のための医薬組成物 |
-
2007
- 2007-09-21 WO PCT/US2007/020445 patent/WO2008036387A2/en not_active Ceased
- 2007-09-21 US US12/311,130 patent/US8334259B2/en active Active
- 2007-09-21 TW TW096135320A patent/TWI486168B/zh not_active IP Right Cessation
- 2007-09-21 JP JP2009529248A patent/JP2010504336A/ja active Pending
- 2007-09-21 CA CA2663547A patent/CA2663547C/en active Active
- 2007-09-21 CN CN200780039878.4A patent/CN101563102B/zh active Active
- 2007-09-21 EP EP07861354A patent/EP2063910A2/en not_active Ceased
-
2012
- 2012-11-20 US US13/682,198 patent/US20130130978A1/en not_active Abandoned
-
2013
- 2013-04-22 JP JP2013089123A patent/JP2013166774A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504336A5 (enExample) | ||
| JP7685737B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| ES2610356T3 (es) | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos | |
| JP6272907B2 (ja) | 代謝障害の処置における組成物及び使用方法 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| JP2014508510A5 (enExample) | ||
| KR20110020903A (ko) | 키메라 나트륨이뇨성 폴리펩티드 및 심장 리모델링 억제 방법 | |
| JP2014512343A (ja) | 多価ヘテロマルチマー足場設計及び構築物 | |
| JP2012511314A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| JP2022008474A5 (enExample) | ||
| KR20210015898A (ko) | Nav1.7 모노클로날 항체 | |
| CN105658228B (zh) | 结合人类补体c5的稳定多肽 | |
| ES2685987T3 (es) | Análogos de péptidos gip | |
| JP2006507229A5 (enExample) | ||
| Zhang et al. | Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain | |
| JPWO2021229076A5 (enExample) | ||
| JPWO2021191447A5 (enExample) | ||
| CN110981967B (zh) | α-芋螺毒素Mr1.1的二聚体、合成方法及应用 | |
| CA2719940A1 (en) | Methods for treating acute myocardial infarction | |
| JP2011515471A5 (enExample) | ||
| RU2776821C2 (ru) | Моноклональное антитело к nav1.7 | |
| KR20200033807A (ko) | 전압-게이팅된 칼슘 채널 보조 서브유닛 α2δ 및 이의 용도 | |
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| WO2022251168A1 (en) | Kidney active fusion proteins and methods of treatment using the same |